Moderna, Inc. (NASDAQ:MRNA)

PRESS RELEASE

published on 03/27/2024 at 11:30, 2 years 6 months ago

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Moderna announces successful clinical readouts for fourth respiratory vaccine candidate meeting Phase 3 endpoints and provides updates on vaccine portfolios, clinical trials, and financial agreements at fifth Vaccines Day event

Clinical Trials Moderna Vaccine Phase 3 Respiratory
BRIEF

published on 03/26/2024 at 12:05, 2 years 6 months ago

Moderna Reports Positive Results in Phase 3 Trial of New COVID-19 Vaccine

Public Health COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283
PRESS RELEASE

published on 03/26/2024 at 12:00, 2 years 6 months ago

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Moderna's mRNA-1283 shows higher immune response than mRNA-1273.222 in Phase 3 trial. Next-generation vaccine offers longer shelf life and storage benefits, paving way for flu-COVID combo vaccine, mRNA-1083

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 MRNA-1273.222
BRIEF

published on 02/29/2024 at 13:00, 2 years 7 months ago

Moderna Announces Fifth Annual Vaccine-Focused Investor Event

Investors Webcast Moderna Investor Event MRNA Vaccines
PRESS RELEASE

published on 02/29/2024 at 13:00, 2 years 7 months ago

Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
Moderna, Inc. announces its fifth annual Investor Event focusing on vaccines and business updates on March 27, 2024. Presentation at 9:00 a.m. ET. Live webcast available on the Moderna website

Webcast MRNA Medicine Moderna Investor Event MRNA Vaccines
BRIEF

published on 02/28/2024 at 13:00, 2 years 7 months ago

Moderna announces participation in investor conferences

Investor Conferences Webcast MRNA Technology Moderna Health
PRESS RELEASE

published on 02/28/2024 at 13:00, 2 years 7 months ago

Moderna to Present at Upcoming Investor Conferences in March 2024
Moderna, Inc. to participate in upcoming investor conferences and showcase advancements in mRNA technology. Visit investors.modernatx.com for webcast details

Investor Conferences Healthcare Moderna Inc. MRNA Technology COVID-19 Vaccines
BRIEF

published on 02/22/2024 at 12:30, 2 years 7 months ago

Moderna announces mixed financial results for 2023 and optimistic outlook for 2024

2023 Financial Results 2024 Forecasts Moderna RSV Vaccine Research Pipeline
PRESS RELEASE

published on 02/22/2024 at 12:30, 2 years 7 months ago

Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Moderna, Inc. reports Q4 revenues of $2.8 billion with a GAAP net income of $217 million. Expects regulatory approvals for RSV vaccine and forecasts 2024 product sales of $4 billion

Financial Results Moderna Inc. RSV Vaccine Product Sales Regulatory Approvals
PRESS RELEASE

published on 02/07/2024 at 06:00, 2 years 8 months ago

Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
Moderna, Inc.'s CEO Stéphane Bancel elected to National Academy of Engineering for distinguished contributions to engineering and manufacturing of pharmaceutical products, including COVID-19 vaccine. Company has 45 mRNA therapeutic and vaccine programs in pipeline

Moderna Inc COVID-19 Vaccine Stéphane Bancel National Academy Of Engineering MRNA Technology

Published on 10/16/2026 at 08:00, 50 minutes ago

Caledonia Mining Corporation Plc: Notification of Relevant Change to Significant Shareholder
Published on 10/16/2026 at 05:55, 2 hours 55 minutes ago

Collective Metals Announces Private Placement of Hard Dollar and Flow-Through Units
Published on 10/16/2026 at 02:10, 6 hours 40 minutes ago

Nova Scotia Silver Explorer TruSilver Metals Corp. Anticipates TSXV Trading Under "TAG" on October 27
Published on 10/16/2026 at 01:45, 7 hours 5 minutes ago

Faraday Copper Closes the Acquisition of the San Manuel Project in Arizona and Mobilizes Drill Rigs
Published on 10/16/2026 at 01:30, 7 hours 20 minutes ago

LNG Energy Group Announces Closing of Second Tranche of Private Placement

View all ACCESSWIRE

Published on 10/16/2026 at 08:00, 50 minutes ago

Aquis Stock Exchange: Suspension of trading
Published on 10/16/2026 at 08:00, 50 minutes ago

Cairn Homes Plc: Transaction in Own Shares
Published on 10/16/2026 at 07:30, 1 hour 20 minutes ago

Steyr Motors and drone specialist Avilus are cooperating on the power supply for the Grille unmanned aircraft system
Published on 10/16/2026 at 07:00, 1 hour 50 minutes ago

PolyPeptide Group: Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.
Published on 10/15/2026 at 22:30, 10 hours 20 minutes ago

Porsche Mission S: the essence of the sports car reinterpreted

View all EQS

Published on 10/16/2026 at 07:30, 1 hour 20 minutes ago

Third Quarter Revenues 2026
Published on 10/15/2026 at 18:50, 14 hours ago

September & first 9 months of 2026 traffic figures - Revision of Traffic assumptions for 2026
Published on 10/15/2026 at 17:45, 15 hours 5 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 10/15/2026 at 17:45, 15 hours 5 minutes ago

VOGO : H1 2026 results.
Published on 10/15/2026 at 17:45, 15 hours 5 minutes ago

THERMADOR GROUPE : Q3 2026

View all LES ECHOS COMFI WIRE

News